Superluminal Medicines Launches With $33 Million Seed Round To Fuel Its Drug Discovery Engine And Pipeline Of Small Molecule Therapeutics
Superluminal Medicines Launches With $33 Million Seed Round To Fuel Its Drug Discovery Engine And Pipeline Of Small Molecule Therapeutics
08/28/23, 11:34 AM
Location
walthamMoney raised
$33 million
Industry
biotechnology
Round Type
seed
Superluminal Medicines Inc., a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created, today announced the closing of a $33 million funding round. The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA. Gaingels also joined in the financing.
Company Info
Location
waltham, massachusetts, united states
Additional Info
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.